Opioid Alternatives Novilla is actively developing opioid alternative pain therapeutics using patented drug delivery methods, indicating a potential sales opportunity for partners or vendors in advanced drug delivery technologies, formulation services, or contract manufacturing to support expanded product development.

Early Stage Revenue With estimated annual revenue in the range of 10 to 25 million and a relatively small team, Novilla may be open to cost-effective partnerships, pilot projects, or strategic collaborations to accelerate market-ready formulations and scale operations without significant upfront commitments.

Technology Stack Novilla employs a modern, cloud-based tech stack including Squarespace, Google Workspace, and Netlify for web presence and collaboration, suggesting potential for technology vendors in website optimization, digital marketing, data analytics, or regulatory submission tooling compatibility.

Public Health Focus The company targets the opioid epidemic—a high-impact public health issue—creating a narrative and regulatory-friendly positioning that could attract partners in healthcare policy, patient support programs, clinical trial CROs, and nonprofit funding collaborations.

Scalability Potential While smaller in size, Novilla’s growth trajectory and the fact it operates in pharmaceutical manufacturing imply opportunities in contract manufacturing, supply chain optimization, packaging, and manufacturing process development for later-stage commercialization or licensing deals with larger players.